

Investor Day

Renishaw Diagnostics Ltd

15th May 2014

Presented by Rupert Jones



Customer needs

Our customers will ultimately be medium to large hospital labs engaged in pathogen (*disease causing micro-organisms*) testing, from 'at risk' or symptomatic patient groups.

Health trust managers are constantly under pressure to reduce costs and improve patient outcomes.

Key to achieving this is an ability to accelerate and improve diagnostic precision, reduce prophylactic (*broad spectrum*) spend and provide a rapid, targeted and precise therapy

Customer needs

The RenDx system provides **automated, high sensitivity testing for multiple pathogens** from a **single patient sample**.

This innovative platform has the potential to change clinical practice by:

- Providing more accurate diagnosis for precise treatment selection and improve patient management
- Reducing time to diagnosis to allow quicker initiation of therapy
- Reducing cost/distress associated with unnecessary or incorrect treatment
- Maximising information from precious samples by testing for multiple pathogens in a single sample
- Automating the process, therefore reducing 'hands on' time for lab staff, enabling more efficient use of valuable resources

Engineering Solution – RenDx

- Currently available and in use on a ‘Research Use Only’ basis, the platform has been very well received by early adopters
- It uses conventional techniques to achieve groundbreaking specificity and sensitivity
- The RenDx platform utilises standard microbiology lab practices prior to proprietary detection technology
- Renishaw is working towards having in place a ‘certified diagnostic system’ and accompanying ‘assays’ (*tests for targeted molecules*) for specific disease conditions





Watch me on **YouTube**™

Gastroenteritis

Invasive Fungal Infection

Infection of CSF

Configurable research kit



Renishaw's first 'targeted solution' – Fungiplex™ assay

Allows detection of most common causative agents of invasive fungal infection (IFI)

Candida	Aspergillus
Candida spp.*	Aspergillus spp.*
<i>C. albicans</i>	<i>A. fumigatus</i>
<i>C. parapsilosis</i>	<i>A. flavus</i>
<i>C. tropicalis</i>	<i>A. niger</i>
<i>C. guilliermondii</i>	Aspergillus. terreus*
<i>C. lusitaniae</i>	
<i>C. dubliniensis</i>	
Candida. krusei*	
Candida. glabrata*	

*reported

- IFDs are predominantly diseases of the diseased
- The two most prevalent pathogens, **Candida** and **Aspergillus**, are responsible > 95% fungal infections
- Candida is the 4th most common bloodstream infection, crude mortality rate 35 - 40%. Aspergillus mortality higher than Candida
- The RenDX with the Fungiplex™ assay is the **only** system that detects both Candida and Aspergillus in a single test.
- Fungiplex assay is not yet CE marked



The RenDx solution

- **Precision diagnostics** rather than broad spectrum treatments
- **Why is this a better approach?**
 - Non-specific signs and symptoms of infection
 - Conventional diagnostic techniques sub-optimal and often require pre-judgement
 - Delays in treatment lead to poorer patient outcomes
 - Leads to over use of expensive, broad spectrum drugs
 - Leads to antibiotic/antifungal resistance

“This approach to multiplex screening could transform the molecular detection of infectious disease”

Helen Fernandes, PhD

Associate Professor and Director Molecular Diagnostics, UMDNJ, NJ, USA

RenDx[®]

Multiplex Assay System

